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ABSTRACT
Breast cancer arising in female BRCA1 mutation carriers is characterized 
by an aggressive phenotype and early age of onset. We performed tandem mass 
spectrometry-based proteomics of secretomes and exosome-like extracellular 
vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models 
to identify extracellular protein biomarkers, which can be used as an adjunct to 
current diagnostic modalities in patients with BRCA1-deficient breast cancer. We 
identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient 
secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster 
most human BRCA1- and BRCA2-related breast carcinomas at the transcriptome 
level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated 
by immunohistochemistry on tissue microarrays of a large panel of 253 human breast 
carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 
and CDH3 was significantly increased in human BRCA1-related breast carcinomas 
relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic 
regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95% confidence interval 
[95% CI], 1.85 - 7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95% 
CI, 1.08 - 5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas 
after adjustment for triple-negative phenotype and age. In conclusion, proteome 
profiling of secretome using murine breast tumor models is a powerful strategy to 
identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We 
demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast 
cancer. These data merit further investigation for early detection of tumors arising 
in BRCA1 mutation carriers.
INTRODUCTION
Approximately 5–10% of female breast cancer are 
believed to be hereditary, caused by a germline mutation 
in the BRCA1 or BRCA2 genes. Owing to an increased 
lifetime cancer risk and young age of onset, mutation 
carriers are eligible for an intensified surveillance 
program consisting of clinical breast examination and 
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annual screening mammography with the intention to 
detect breast cancer at a potentially curable stage. The 
accuracy of screening mammography to detect early breast 
lesions is, however, limited in young women due to their 
dense breast tissue [1–3]. Magnetic resonance imaging 
as an adjunct to screening mammography has improved 
sensitivity to detect suspected breast lesions [4, 5], 
but interval breast cancer rates remain substantial and 
specificity is limited [6]. There is therefore a compelling 
need to improve current clinical management i.e. early 
breast cancer detection in BRCA mutation carriers. 
Tumor cell-secreted proteins, constituting the 
secretome, have been proposed as biomarkers potentially 
detectable in the blood circulation or other body fluids [7]. 
Proteomic profiling of cancer secretomes from genetically 
engineered mouse models (GEMMs) with tissue-specific 
deletion of targeted genes may point towards relevant 
proteins, that are closely associated with the altered gene. 
For example, employing proteomic analysis on conditional 
GEMMs for BRCA1-deficient and -proficient breast 
tumors, we have previously identified a tissue-specific 
signature of 45 proteins, that can discriminate human 
BRCA1- and BRCA2-deficient breast carcinomas from 
other familial or sporadic breast carcinomas [8–10]. The 
question remains whether this signature is applicable for 
routine clinical assessment, but our findings, together with 
other reports, underscore the usefulness of GEMMs and 
the potential of proteomics as an approach for discovery 
of novel protein biomarkers. 
In the current study, we applied an in-depth 
proteomic profiling of secretomes and extracellular 
vesicles (EVs) of BRCA1-deficient and -proficient breast 
tumor cell lines derived from three validated GEMMs. 
Comparative analysis revealed that BRCA1 deficiency 
has a marked effect on the repertoire of released proteins. 
Moreover, the majority of these proteins has been shown 
to be detectable in human plasma, indicative of their 
potential as blood-based markers. As a first step to evaluate 
clinical relevance, we analyzed protein expression of 
topoisomerase I (TOP1) and P-cadherin (CDH3) in a large 
panel of breast cancer tissues from BRCA1/2 mutation 
carriers and women without a hereditary predisposition. 
We report that TOP1 and CDH3 were expressed to a 
higher extent in BRCA1-related breast carcinomas relative 
to sporadic breast carcinomas, highlighting their potential 
clinical usefulness for breast cancer detection in women 
with a BRCA1 mutation.
RESULTS
Protein profiling of BRCA1-deficient and 
-proficient breast tumor cell line secretomes
For this study, we used primary mammary tumor 
cell lines derived from a well-characterized GEMM for 
BRCA1-deficient breast cancer (K14Cre;Brca−/−;p53−/−) 
and from two different GEMMs for BRCA1-proficient 
breast cancer (K14Cre;p53−/− and K14Cre;Cdh1−/−;p53−/−). 
To identify secreted proteins potentially associated with 
BRCA1 deficiency, we analyzed secretomes (in biological 
triplicate for each cell line) using a robust and reproducible 
label-free proteomics workflow [8, 11] as shown in 
Figure 1. Reproducibility of protein identification and 
quantification from biological triplicate experiments was 
high (an overlap of identified proteins of > 80% and the 
coefficient of variation of 14–15% of the overlapping 
proteins across triplicate experiments of each group, 
Supplementary Figure 1A).
A total of 2,107 proteins were identified in at 
least one of nine secretome samples. A large proportion 
of proteins (59%) was predicted to be secreted via 
classical (24–32%) or non-classical (29–33%) secretory 
pathways as determined with SignalP and SecretomeP 
(Supplementary Figure 2 and Supplementary Table 1). Of 
2,107 proteins, 1,365 proteins were commonly identified 
among the three cell lines (in at least one triplicate, see 
Supplementary Figure 1B). Unsupervised hierarchical 
clustering analysis on all proteins demonstrated a distinct 
separation between BRCA1-deficient and BRCA1-profient 
groups indicating that the proteomic portrait of secretome 
may be influenced by the BRCA1 gene knockout status 
(Supplementary Figure 3).
A total of 912 significantly differentially released 
proteins between BRCA1-deficient and BRCA1-proficient 
secretomes were identified. Of these, 509 proteins were 
more abundantly present in BRCA1-deficient secretomes, 
whereas 403 proteins were less abundantly released 
(Supplementary Table 1). 
Murine BRCA1-deficient proteins in human 
BRCA1/2-mutated breast cancer
To examine human relevance, we analyzed the 
509 upregulated BRCA1-deficient proteins in an mRNA 
dataset as published by Jönsson et al. [12]. This dataset 
contains 359 patients with breast cancer, among which 
there were 22 BRCA1 mutation cases, 32 BRCA2 mutation 
cases and 305 sporadic cases. Among the upregulated 
BRCA1-deficient proteins, 254 proteins could be mapped 
to the corresponding mRNA transcript levels. Hierarchical 
cluster analysis showed that the mapped mRNA transcripts 
could separate the majority of the BRCA1/2-deficient 
breast carcinomas from the majority of sporadic breast 
carcinomas (Figure 2). A total of 50 mRNA transcripts were 
also overexpressed in BRCA1/2-deficient breast cancer 
relative to sporadic breast cancer (p < 0.1, Supplementary 
Table 2). These included chromatin remodeling proteins 
including SMC2, SMC1A, TOP2A, DNMT1 and DEK. 
Two candidates, namely SMC1A and TOP2A, were part 
of our previously identified 45 proteins BRCA-like tissue 
signature [8]. Although protein abundance and mRNA 
expression may not consistently correlate because of e.g. 
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post transcriptional regulation, our findings suggest that 
proteins highly released by BRCA1-deficient breast cancer 
cell line, when mapped to mRNA transcript, may enrich 
BRCA1/2-related breast cancer. 
Selection of candidate non-invasive BRCA1-
deficiency breast tumor biomarkers and in silico 
exploration of their connectivity and biological 
functions 
To reduce the list of differentially released proteins 
to the most discriminatory ones, we applied more 
stringent selection criteria (p < 0.01, fold change > 5 
and total spectral count of ≥ 6 in biological triplicates), 
resulting in 215 proteins highly enriched in the BRCA1-
deficient secretome and 100 proteins highly enriched in 
the BRCA1-proficient secretome (Supplementary Table 2). 
Interestingly, the proportion of nuclear proteins was 
higher in these 215 BRCA1-deficient proteins compared 
to that in the 100 BRCA1-proficient proteins (25 vs 14%, 
Supplementary Figure 4).
To explore the connectivity and biological functions 
of the 215 highly discriminatory BRCA1-deficient 
proteins, we used the STRING tool in conjunction with 
gene ontology (GO) analysis. Detailed GO results are 
shown in Supplementary Table 3. This analysis yielded 
one large network of 155 proteins that consisted of 
seven regions of densely connected proteins (nodes) 
using the ClusterViz tool (minimum size of five proteins, 
Figure 3). These sub-networks were associated with the 
following biological processes as determined by BinGO 
analysis: 1. “multi-cellular organismal process” with sub-
terms “angiogenesis” and “cell surface receptor-linked 
signaling pathway”; 2.”chromosome organization” and 
“nucleic acid metabolic process” including the BRCA-
like signature protein TOP1, a protein involved in DNA 
topological processes, and nucleophosmin (NPM1), a 
protein functionally associated with BRCA1-deficient 
double-stranded DNA repair; 3. “RNA processing” and 
“RNA splicing”, including PRPF8 and SMC1A, that are 
both part of the previously published 45 protein BRCA-
like tissue signature; 4. “metabolic process” with sub-
terms “fatty acid metabolic process” and “lipid metabolic 
process”; 5. a cluster centered around protein translation 
with five out of eight proteins involved in the biological 
process “translation” (more specifically in “translational 
elongation”) and three in “regulation of translation”; 6. 
“carbohydrate metabolic process”; 7. this cluster had no 
clear association with any biological processes, but two 
Figure 1: Experimental workflow to identify and validate BRCA1 deficiency protein biomarkers. The discovery experiment 
included three groups consisting of one BRCA1-deficient model and two BRCA1-proficient models, with three animals in each group. 
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proteins, HYOU1 and HSP90B1, are involved in response 
to hypoxia (Figure 3).
The network of the 100 proteins highly abundantly 
released in BRCA1-proficient secretome is shown in 
Supplementary Figure 5 and contains three sub-networks 
associated with “metabolic process”, “cell adhesion” and 
“cellular component movement”.
In conclusion, the 215 proteins highly enriched 
in the BRCA1-deficient secretome are involved in cell-
cell contact and communication, chromatin processes, 
RNA processing, protein translation and include several 
proteins that have been linked to BRCA1-deficient breast 
cancer. BRCA1-proficient cells release far less proteins and 
comprise a limited and totally different set of functions.
Human plasma proteome
We integrated the 215 highly abundant proteins of 
the BRCA1-deficient secretome into the public database of 
the human plasma proteome. Among these proteins, 162 
(75%) were identified in plasma (Supplementary Table 2). 
This in silico analysis indicated the potential of most 
proteins to enter the blood circulation and may assist in 
prioritizing candidate markers for future studies.
Exosome-like EVs as carriers of BRCA1-deficient 
proteins
As mentioned above, many proteins detected in the 
secretomes were predicted to be non-classically secreted. 
Among them, a large proportion was of nuclear origin. 
This observation prompted us to explore whether these 
proteins might be released via the non-classical, vesicle-
mediated secretory pathway. Therefore, we performed 
proteomics of EVs isolated from the same BRCA1-
deficient and BRCA1-proficient breast tumor cell lines 
resulting in 2,149 proteins (Supplementary Figure 6 and 
Supplementary Table 4). Exosomes are a class of EVs of 
endosomal origin. Multiple exosome-associated proteins 
were present and most proteins, including Alix, Tsg101 
and CD63, were highly enriched in the EV fraction relative 
to the soluble secretome fraction (Figure 4A). Exosome 
enrichment was also confirmed by Western blot analysis 
of Alix (Figure 4B). The key biological processes (protein 
transport and vesicle-mediated transport) and molecular 
functions (GTP and ribonucleotide binding) were in line 
with the presence of several Rab GTases, known to be 
involved in vesicle formation, trafficking and transport 
[13] (Supplemental Figure 7). 
A preliminary comparison of EV proteomes between 
BRCA1-deficient and -proficient groups identified 490 
differentially abundant proteins. A total of 405 proteins 
were enriched in BRCA1-deficient vesicles. Major 
biological pathways of these 405 BRCA1-deficient 
proteins included DNA replication, RNA degradation and 
RNA splicing (Supplementary Figure 8).
A relatively large number of nuclear proteins 
was present among the 405 BRCA1-deficient proteins 
(Supplementary Figure 9). Overlap analysis revealed that 
111 proteins were upregulated in the BRCA1-deficient 
Figure 2: Hierarchical cluster analysis of the mRNA dataset for BRCA1/2 breast carcinomas on the basis of gene 
expression of mapped BRCA1-deficient proteins. Hierarchical clustering of 254 upregulated BRCA1-deficient proteins showed a 
separation of most human BRCA1/2-mutated breast carcinomas from sporadic breast carcinomas, when mapped to the mRNA dataset as 
published by Jönsson et al (Breast Cancer Res 2010).
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secretome as well as in the BRCA1-deficient EVs relative 
to BRCA1-proficient counterparts. Among them were 
several nuclear proteins, which have previously been 
identified in BRCA1-deficient breast carcinomas (TOP1, 
SMC3, SSRP1 and DHX9, Supplementary Figure 10). 
Moreover, EV-mediated release of nuclear proteins was 
exemplified by TOP1, which was enriched in secretome 
and EVs of BRCA1-deficient group and its abundance 
was higher in EVs than in the secretome (Supplementary 
Figure 11). Taken together, intracellular (nuclear) proteins 
of BRCA1-deficient breast tumor cells (e.g. TOP1) 
released through exosome-like EVs may represent putative 
candidates related to BRCA1-deficient breast cancer.
Validation of CHD3 and TOP1 in human breast 
carcinomas
Two proteins highly abundant in the BRCA1-
deficient secretome, namely CDH3 and TOP1, were 
selected for validation in tumor tissue samples of breast 
cancer patients. CDH3, a plasma membrane protein, is 
involved in cell adhesion and has been proposed as a tissue 
marker in human BRCA1-deficient breast cancer as well as 
a serum marker in basal-like breast cancer [14, 15]. TOP1 
is a nuclear protein involved in DNA replication and was 
selected for validation because of its high abundance in 
BRCA1-deficient secretome and EVs compared to BRCA1-
proficient counterparts. Moreover, TOP1 is present in our 
previously identified BRCA-like tissue signature.
Protein expression of CDH3 and TOP1 was 
analysed in a panel of 253 human breast carcinomas 
comprising 102 BRCA1-related, 49 BRCA2-related and 
102 sporadic breast carcinomas. Clinical and tumor 
characteristics are shown in Table 1. The majority of 
tissue samples concerned ductal carcinomas (86–90%). 
Significant differences among the three groups were noted 
with respect to age of histological diagnosis (p < 0.001), 
histological grade (p = 0.003), estrogen receptor (p < 0.001), 
progesterone receptor (p < 0.001) and HER2 expression 
(p = 0.039). 
Receptor status (ER, PgR and HER2) was completed 
in 250 samples. About 74% of BRCA1-related breast 
carcinomas, 23% of BRCA2-related breast carcinomas 
and 13% of sporadic breast carcinomas had triple negative 
phenotype lacking ER, PgR and HER2 expression (p < 
0.001). A significantly higher rate was found in BRCA1-
related compared with BRCA2-related breast carcinomas 
(p < 0.001) as well as with sporadic carcinomas (p < 
Figure 3: Protein-protein interaction network of 215 highly upregulated proteins in BRCA1-deficient relative to 
BRCA1-proficient secretomes. Nodes represent proteins while the edges represent direct (physical) and indirect (functional) 
associations. Dashed lines indicate top seven most populated clusters identified by ClusterViz cluster analysis. Table shows representative 
biological processes of the seven clusters according to BinGO gene ontology analysis.
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0.001), while no difference was found between BRCA2-
related breast carcinomas and sporadic breast carcinomas 
(p = 0.11). Triple negative breast cancer appeared to be 
diagnosed in women of younger age (< 45 years) compared 
with those aged ≥ 45 years (58% vs 27%, p < 0.001). 
Representative staining results for TOP1 and CDH3 
are shown in Figure 5 (high quality image of TOP1 and 
CDH3 staining is available in Supplementary Figure 12). 
The rates of TOP1-positive tumors were significantly 
different among the three groups (p = 0.004). TOP1 
overexpression was mostly observed in BRCA1-related 
(60%) and in BRCA2-related breast carcinomas (59%) 
as compared to sporadic breast carcinomas (35%). 
Comparison between BRCA1-related and sporadic breast 
carcinomas demonstrated a significant difference in 
TOP1 expression (p = 0.002). With regard to CDH3, a 
significant difference was found among the three groups 
with 76% of BRCA1-related, 37% of BRCA2-related and 
22% of sporadic breast carcinomas being CDH3 positive 
(p < 0.001). There was a significant difference between 
BRCA1-related and sporadic breast carcinomas in terms 
of CDH3-positive cases (p < 0.001). Of 195 breast cancer 
samples with TOP1 and CDH3 available, 57 samples were 
positive for TOP1 and CDH3 and 138 samples were TOP1 
and/or CDH3 negative (79 positive for either of the two 
markers and 59 samples negative for both markers). When 
both markers were combined, significant differences in 
the rate of TOP1- and CHD3-positive tumors were found 
among the three groups (p < 0.001). Of note, the rates of 
TOP1 and CDH3 positivity were the highest in BRCA1-
related breast carcinomas (48%) followed by BRCA2-
related (24%) and sporadic breast carcinomas (7%).
Multiple logistic regression was performed to 
estimate the predictive effects of TOP1 or CDH3 for 
BRCA1/2-related breast carcinomas when adjusted for triple 
negative breast cancer and age (Table 2). We chose to use 
Table 1: Clinical and tumor characteristics of breast carcinoma tissues
Sporadic breast 
cancer 
(n = 102)
n (%)
BRCA1-mutated 
breast cancer 
(n = 102)
n (%)
BRCA2-mutated 
breast cancer 
(n = 49)
n (%)
P value
Tumor type
 Ductal 
 Lobular 
 Medullary 
 Other
88 (86)
10 (10)
0 
4 (4)
89 (87)
4 (4)
4 (4)
5 (5)
44 (90)
3 (6)
0 
2 (4)
0.088
Age
 < 45
 ≥ 45
16 (16)
86 (84)
62 (62)
38 (38)
18 (37)
30 (63)
< 0.001
Grade
 1
 2
 3
8 (8)
32 (34)
55 (58)
3 (3)
17 (18)
77 (79)
0 
18 (39)
28 (61)
0.003
Estrogen receptor 
 Positive
 Negative 
85 (83)
17 (17)
27 (27)
73 (73)
36 (75)
12 (25)
< 0.001
Progesterone receptor
 Positive 
 Negative 
61 (60)
41 (40)
17 (17)
84 (83)
22 (46)
26 (54)
< 0.001
HER2
 Positive 
 Negative 
11 (11)
91 (89)
2 (2)
98 (98)
3 (6)
45 (94)
0.039
TOP1
 Positive 
 Negative 
24 (35)
45 (65)
56 (60)
38 (40)
26 (59)
18 (41)
0.004
CDH3
 Positive 
 Negative 
17 (22)
62 (78)
68 (76)
22 (24)
14 (37)
24 (63)
< 0.001
TOP1 and CDH3 
TOP1 and CDH3 positive
TOP1 and/or CDH3 negative
5 (7)
63 (93)
43 (48)
46 (52)
9 (24)
29 (76)
< 0.001
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BRCA1/2-related breast carcinomas as an endpoint because 
both BRCA1/2 mutations confer an increased risk of breast 
cancer. TOP1 expression was independently associated with 
BRCA1/2-related breast carcinomas (adjusted odds ratio 
[OR] 3.75; 95% confidence interval [95% CI], 1.82–7.71, 
p < 0.001). Similarly, an independent association of CDH3 
expression for BRCA1/2-related breast carcinomas was 
found (adjusted OR 2.44; 95% CI, 1.08–5.49, p = 0.032). 
When TOP1 and CDH3 were combined, there was a 
significant association between breast carcinomas with 
positive TOP1 and CDH3 and BRCA1/2 mutations (adjusted 
OR 5.05; 95% CI, 1.75–14.6, p = 0.003). 
Table 2: Multiple logistic regression of TOP1 and CDH3 for BRCA1/2-related breast carcinomas
Independent variable Beta
Standard 
error
Adjusted odds ratio 
(95% CI)
P value
Constant 
TNBC (yes vs no)
Age (< 45 vs ≥ 45 yrs)
TOP1 (positive vs negative)
−1.10
2.09
1.59
1.32
0.31
0.43
0.41
0.37
8.07 (3.46–18.8)
4.88 (2.18–11.0)
3.75 (1.82–7.71)
< 0.001
< 0.001
< 0.001
< 0.001
Constant
TNBC (yes vs no)
Age (< 45 vs ≥ 45 yrs)
CDH3 (positive vs negative)
−0.80
1.41
1.46
0.89
0.23
0.46
0.39
0.41
4.08 (1.64–10.1)
4.30 (2.00–9.24)
2.44 (1.08–5.49)
< 0.001
< 0.001
< 0.001
0.032
Constant
TNBC (yes vs no)
Age (< 45 vs ≥ 45 yrs)
TOP1 and CDH3 (positive vs TOP1 and/or CDH3 
negative)
−0.72
1.66
1.46
1.62
0.24
0.43
0.41
0.54
5.28 (2.28–12.2)
4.31 (1.93–9.63)
5.05 (1.75–14.6)
< 0.001
< 0.001
0.003
0.003
TNBC, triple-negative breast cancer.
Figure 4: Exosome-associated proteins identified in soluble secretome and extracellular vesicle fractions. (A) 
Quantification of exosome-associated proteins is presented by normalized spectral counts. (B) Western blot of Alix in soluble secretome 
and extracellular vesicle fractions. Cropped images of Western blot showing a common exosome marker (Alix) in soluble secretome and 
extracellular vesicle fractions. 
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DISCUSSION
With proteomic analysis of breast tumor GEMM-
derived secretomes, we identified a series of released 
proteins associated with BRCA1 status. Most of these 
proteins are detectable in the blood circulation according 
to the human plasma proteome database, suggesting their 
clinical usefulness in blood-based testing for the prediction 
of BRCA1 deficiency. Increased levels in TOP1 and CDH3 
were validated in a large population-based series of breast 
cancer patients with a BRCA1/2 mutation. These data 
merit further investigation.
The applicability of our results from murine breast 
tumor models to human BRCA1-related breast cancer 
is well supported by several levels of evidence. Many 
BRCA1-deficient candidate proteins identified play 
a role in DNA repair and are associated with BRCA1 
function. These included NPM1 [16], SMC1A [17], 
SMC3 [18], TOP1 [19], HMGB2 [20], DNMT1 [21], 
SRSF1 [22], EIF4G1 [23] and HDAC2 [24]. Further 
support was provided by our in silico analysis showing 
that BRCA1 candidate proteins, when mapped to mRNA 
transcripts, could cluster BRCA1- and BRCA2-related 
breast cancer cases. More importantly, we validated two 
candidate proteins demonstrating, in accordance with 
animal data, increased expression in human BRCA1-
related breast carcinomas. Finally, underscoring the 
potential use as non-invasive biomarker, 75 of protein 
candidates found in secretome including TOP1 and 
CDH3, are detectable in human plasma [25, 26]. 
Together, our data demonstrate the potential usefulness 
of breast tumor GEMM-derived secretome biomarkers 
for non-invasive diagnosis of human BRCA1-deficient 
breast cancer.
Interestingly, several nuclear-specific proteins were 
more abundantly present in the BRCA1-deficient compared 
to the BRCA1-proficient secretome. We demonstrated that 
exosome-like EVs may account for non-classical secretion 
of these nuclear proteins. EVs and especially exosomes 
have previously been implicated in many cellular 
functions, including cell-cell communication, tumor 
growth, metastases formation and angiogenesis [27, 28]. 
EVs have also been proposed to facilitate the intercellular 
transfer of a spectrum of cell-type specific factors e.g. 
miRNA and proteins. Interestingly, the molecular content 
of EVs has been shown to reflect the cells of origin, 
thereby underscoring the potential of EV protein profiling 
for the use of BRCA1 detection. 
In the present study, TOP1 was detected at an 
increased level in the BRCA1-deficient secretome and 
exosome-like vesicles as well as in human BRCA1-
related breast carcinomas. Furthermore, multiple logistic 
regression analysis showed that TOP1 positivity was 
significantly associated with BRCA1/2 mutations (adjusted 
OR = 3.75, p < 0.001). This association was independent 
of the presence of TNBC and age suggesting that 
Figure 5: Immunohistochemical staining of TOP1 and CDH3 in BRCA1-deficient and proficient breast cancer. 
Representative positive and negative staining of TOP1 (upper panel) and CDH3 (lower panel) are shown. 
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assessment of TOP1 may substantially improve prediction 
of BRCA1/2 mutations, in particular in breast carcinomas 
with hormone-receptor positive or HER2 positive breast 
cancer diagnosed in women aged ≥ 45 years. Our findings 
are in line with preclinical data reporting the involvement 
of TOP1 in DNA single-strand break repair in conjunction 
with BRCA1. In this regard, TOP1 has been described 
as a prominent target in BRCA1-deficient breast cancer 
[29]. TOP1 inhibitors indirectly induce DNA damage 
and are currently under investigation for their potential in 
targeting tumors with homologous recombination defects 
[30]. Moreover, TOP1 degradation has been described 
to be mediated by BRCA1 and accumulation of TOP1 
has been observed in case of BRCA1 dysfunction [31]. 
Here, we identified TOP1 to be preferentially present in 
BRCA1-deficient EVs. Therefore, it may be speculated 
that accumulated TOP1 is partly due to release via EVs.
We demonstrated increased CDH3 levels in a large 
panel of human BRCA1-related breast carcinomas. Similar 
to TOP1, increased CHD3 expression was associated with 
BRCA1/2-related breast carcinoma, independent of TNBC 
and age. These result confirmed its potential as marker for 
BRCA1/2 mutations. In previous studies, an increased level 
of CDH3 has been detected in a small cohort of BRCA1-
deficient breast cancer [15], as well as in nipple aspirate 
fluid and serum obtained from women with basal-like breast 
tumors [14]. Gorski et al. [25] have shown that BRCA1 is 
a transcriptional repressor of CDH3, thereby providing a 
biological explanation for our observation of the strong 
presence of CDH3 in BRCA1-deficient breast carcinomas 
and large abundance in BRCA1-deficient secretome. 
MATERIALS AND METHODS
Mouse models and cell line isolation and culture
BRCA1-deficient breast tumors from 
K14Cre;Brca−/−;p53−/− GEMMs resemble human BRCA1-
deficient breast cancer as determined by histopathology 
and genotyping. BRCA1-proficient breast tumors from 
K14Cre;p53−/− GEMMs resemble human sporadic 
basal-like breast cancer, whereas BRCA1-proficient 
breast tumors from K14Cre;Cdh1−/−;p53−/− GEMMs are 
histopathologically similar to human pleomorphic lobular 
breast cancer [10]. 
Primary breast tumor cells were isolated from tumor-
bearing GEMMs as described in detail elsewhere [32]. Cell 
lines were cultured at 37°C and 5% CO2 atmosphere in 
DMEM/F12-GlutaMAX medium (Gibco) supplemented 
with 10% fetal calf serum (FCS), 1% penicillin-
streptomycin (Lonza), 5 μg/ml insulin, 5 ng/ml epidermal 
growth factor (Life Technologies) and 5 ng/ml cholera 
toxin. Serum-free medium contains the above-mentioned 
supplements without FCS. All animal experiments 
were approved by the animal research committee of the 
Netherlands Cancer Institute.
Preparation of breast tumor cell line secretomes
Cell line secretomes were prepared as described 
before [11]. In brief, tumor cells were grown until 70–80% 
confluency and incubated in serum-free medium overnight 
for 22–24 h. The conditioned medium (referred to as 
secretome) was removed from cell debris and concentrated 
to a final volume of ~50 μL using 3 kDa cutoff spin filter 
(Millipore). The samples supplemented with Sodium 
Dodecyl Sulfate (SDS) sample buffer containing 100 mM 
dithiotreitol were stored at −80°C until further analysis.
Extracellular vesicles isolation 
Isolation of EVs was performed by ultracentrifugation 
according to an established method [33, 34]. In short, ~5 
mL concentrated secretome was subjected to differential 
centrifugation steps at 12,000 × g for 1 h and at 110,000 × 
g for 2 h using a Beckman SW40TI rotor. The supernatant, 
further referred to as the soluble protein fraction, was 
collected and the EV pellet was centrifuged at 110,000 
× g for another 2 h and suspended in SDS sample buffer 
before storage at −80°C. The soluble protein fraction was 
concentrated and stored at −80°C supplemented with SDS 
sample buffer.
Western blot
EV and soluble protein fractions were 
immunoblotted with anti-Alix primary antibody (3A9, Cell 
signaling), followed by secondary antibody conjugated 
with IRDye 680 (Rockland). Fluorescent signals were 
detected with an Odyssey infrared imaging system (LI-
COR Biosciences).
Proteomics by tandem mass spectrometry and 
database searching
Proteins from secretomes or EVs were fractionated 
by one-dimensional electrophoresis followed by trypsin 
in-gel protein digestion and nanocapillary liquid 
chromatography-tandem mass spectrometry (GeLC-MS/
MS) [11]. Secretome tryptic digests were measured on 
an Ultimate 3000 nanoLC system (Dionex LC-Packings) 
on-line coupled to the LTQ-FT hybrid mass spectrometer 
(Thermo Fisher) using a top5 MS/MS method. EV tryptic 
digests were measured on a Q Exactive mass spectrometer 
(Thermo Fisher) coupled to a Ultimate 3000 nanoLC 
system (Dionex LC-Packings). The raw MS/MS data were 
processed as described before [8]. 
Tissue microarray and immunohistochemistry
The study group comprised 253 cases of human 
breast carcinomas, among which were 102 BRCA1, 
49 BRCA2 germline mutation-related cases and 102 
breast cancer cases not known to have a BRCA1/2 
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mutation (further denoted as “sporadic”). Four μm thick 
sections were stained with hematoxylin and eosin for 
histopathology. Tumor type was assessed according 
to WHO and tumors were graded according to the 
Nottingham grading system. Tissue microarrays were 
constructed and stained for estrogen receptor (ER, 1:100, 
DAKO), progesterone receptor (PR, 1:100, DAKO), 
human epidermal growth factor receptor-2 (HER2, 1:100, 
Thermo Scientific [Neomarkers]), TOP1 (1:100, Abcam) 
and CDH3 (extracellular domain, 1:400, BD Biosciences, 
Pharmingen). Appropriate positive and negative controls 
were used throughout. 
All specimens were scored by a single pathologist 
(PJvD), who was blinded to the origin of tumors. For ER 
and PR, the percentage of positive nuclei was scored. 
Samples with ≥ 10% immunopositive malignant cells 
were classified as ER or PR positive. For HER2 and 
CDH3, membranous staining was scored according to the 
DAKO scoring system as 0, 1+, 2+ and 3+, considering 
HER2 3+ and CDH3 1+, 2+ and 3+ cases as positive. 
For TOP1, the percentage of positive nuclei and the 
intensity of staining were scored. The product of the 
percentage of positive nuclei and the intensity of staining 
was calculated and cases above 170 were classified as 
positive. Since we used archival pathology material, 
which does not interfere with patient care and does 
not involve the physical involvement of the patient, no 
ethical approval was required according to institutional 
and Dutch regulations under an opt out system (reviewed 
by van Diest et al. [35]).
Data analysis
For each protein, spectral counts were normalized for 
the total spectral counts in each sample. The normalized 
spectral counts were used for further comparative analyses. 
Differences in relative protein abundance, expressed as 
normalized spectral count, between BRCA1-deficient 
and -proficient GEMMs were analyzed using the beta 
binomial test [36–38]. P < 0.05 was considered statistically 
significant. Hierarchical unsupervised clustering was 
carried out on all identified proteins. Associations between 
immunohistochemistry (IHC) expression of proteins were 
tested by Pearson’s Chi-square test. Multiple logistic 
regression was used to estimate the predictive effects of 
candidate biomarkers for identifying mutation carriers 
while adjusting for confounding factors. All statistical 
analyses were carried out with SPSS and R.
The clinical relevance of protein candidates was 
evaluated by analyzing the gene expression dataset 
containing mRNA expression of BRCA1/2-related and 
sporadic breast carcinomas as published by Jönnson 
et al. [12]. As clustering parameters for the gene 
expression dataset, we used a Spearman rank correlation 
in combination with the Ward’s distance. mRNA levels 
of candidate proteins between BRCA1/2-deficient breast 
cancer and sporadic breast cancer were evaluated with 
Mann-Whitney U test using P < 0.1 as an arbitrary cut-
off. To identify putative blood-based markers, protein 
candidates were evaluated in different human plasma 
proteome databases [39, 40].
Ingenuity pathway analysis software (Ingenuity 
Systems) and DAVID tool [41] were used to analyze 
biological functions and deregulated pathways in BRCA1-
deficient breast cancer. SignalP and SecretomeP were 
used to predict proteins potentially undergoing classical 
and non-classical secretion [13, 42]. Cytoscape (version 
2.7.2) [43] and STRING tool (version 9.0) [44] were used 
to analyze protein interactions as well as for network 
analysis. Cytoscape ClusterViz plugin was employed to 
identify clusters of biological networks [45].
CONCLUSIONS AND OUTLOOK
Our study provides a promising set of secreted or 
excreted proteins that could find use in early non-invasive 
detection of tumors that arise in BRCA1 mutation carriers 
and that might support management of treatment choice. 
Further validation of the detection of released biomarker 
proteins in body fluids, such as blood or nipple aspirate 
fluid, is a vital aspect to be resolved for future clinical 
applications. At present, this validation is hampered by 
limited availability of sensitive ELISA assays for the 
majority of candidate protein biomarkers. Therefore, 
we here applied immunohistochemistry for verification 
of increased expression of TOP1 and CDH3 in BRCA1-
deficient breast carcinomas. New multiplex technologies, 
such as targeted mass spectrometry, may provide better 
opportunities for future large-scale validation in biofluids. 
Importantly, up to 75% of the BRCA1 deficiency-
associated secretome proteins are detectable in blood, 
thereby underscoring the value of our proteomic strategy. 
Future studies are warranted to assess the non-invasive 
diagnostic power of these proteins for early detection of 
breast tumors in cohorts of BRCA1 mutation carriers. 
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